Cargando...
Brodalumab in psoriasis: evidence to date and clinical potential
Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to mark...
Gardado en:
| Publicado en: | Drugs Context |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioExcel Publishing Ltd
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6474429/ https://ncbi.nlm.nih.gov/pubmed/31024633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212570 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|